Below are the most recent publications written about "Interferon Type I" by people in Profiles.
-
Steinbuck MP, Seenappa LM, Zhan W, Palmer E, Jung MM, Jakubowski A, Cabana-Puig X, McNeil LK, Haqq CM, Fitzgerald KA, DeMuth PC. Lymph node-targeted DNA engages TBK1/IFN-I-driven innate immunity to induce potent T cell responses and durable memory in mice and NHPs. Sci Adv. 2026 May 29; 12(22):eaec1416.
-
Wang Y, Afshari K, Haddadi NS, Lopes CS, Eng CL, Whiteman LM, Martinez N, Kyawe PP, Anufrieva KS, Wei K, Frieda K, Rosenbach M, Vleugels RA, Gallucci S, Harris JE, Rashighi M, Garber M. A spatially coordinated keratinocyte-fibroblast circuit recruits MMP9+ myeloid cells to drive type I interferon-driven inflammation in photosensitive autoimmunity. Nat Immunol. 2026 Jun; 27(6):1184-1196.
-
Gong W, Taner HF, Wu Y, He Y, Zhou X, Li Z, Hu X, Ursin C, Debnath KC, Okuyama K, Hu Q, Donnelly CR, N?r F, Perera CD, Bellile E, Yunesi A, Zhai Z, Zhao M, Cheng W, Fitzsimonds ZR, Broses L, Li J, Demehri S, Nagrath D, Wolf GT, Sikora AG, Yu Y, Wen H, Wei L, Chinn SB, Myers JN, Akira S, Xie Y, Moon JJ, Lei YL. BATF2 is a glutamine-responsive tumour suppressor required for type-I interferon-dependent anti-tumour immunity. Nat Commun. 2025 Dec 29; 17(1):1271.
-
Casta?o D, Bettini E, Kumar B, Chudnovskiy A, Siv A, Protti G, Nakadakari-Higa S, Ceglia S, De Luna N, Chiu JE, Lederer K, Li SH, Ibrahim H, Muramatsu H, Mdluli T, Abraham E, Sahingur SE, Maillard I, Tam YK, Shin S, Hensley SE, Miner JJ, Lipinszki Z, Reboldi A, Pardi N, Spreafico R, Victora GD, Locci M. Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses. Cell. 2025 Dec 24; 188(26):7461-7480.e23.
-
Kurt-Jones EA, Gulati S, King M, de Oliveira RB, Rice PA, Zheng B, Shaughnessy J, Edwards JL, Hertzog PJ, Ram S, Golenbock DT. Interferon-epsilon, an estrogen-induced type I interferon, is uniquely exploited by Neisseria gonorrhoeae via effects on sialic acid metabolism. Cell Host Microbe. 2025 Jul 09; 33(7):1133-1145.e4.
-
Arowosegbe A, Guo Z, Vanderleeden E, Derr AG, Wang JP. Janus kinase inhibition prevents autoimmune diabetes in LEW.1WR1 rats. J Autoimmun. 2025 Feb; 151:103358.
-
Chibaya L, DeMarco KD, Lusi CF, Kane GI, Brassil ML, Parikh CN, Murphy KC, Chowdhury SR, Li J, Ma B, Naylor TE, Cerrutti J, Mori H, Diaz-Infante M, Peura J, Pitarresi JR, Zhu LJ, Fitzgerald KA, Atukorale PU, Ruscetti M. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. Sci Transl Med. 2024 08 28; 16(762):eadj9366.
-
Bazzone LE, Zhu J, King M, Liu G, Guo Z, MacKay CR, Kyawe PP, Qaisar N, Rojas-Quintero J, Owen CA, Brass AL, McDougall W, Baer CE, Cashman T, Trivedi CM, Gack MU, Finberg RW, Kurt-Jones EA. ADAM9 promotes type I interferon-mediated innate immunity during encephalomyocarditis virus infection. Nat Commun. 2024 May 16; 15(1):4153.
-
Ziegler CGK, Owings AH, Galeas-Pena M, Kazer SW, Miao VN, Navia AW, Tang Y, Bromley JD, Lotfy P, Sloan M, Laird H, Williams HB, George M, Drake RS, Pride Y, Abraham GE, Senitko M, Robinson TO, Diamond G, Lionakis MS, Shalek AK, Ordovas-Montanes J, Horwitz BH, Glover SC. An enhanced IL17 and muted type I interferon nasal epithelial cell state characterizes severe COVID-19 with fungal coinfection. Microbiol Spectr. 2024 06 04; 12(6):e0351623.
-
Lin QXX, Rajagopalan D, Gamage AM, Tan LM, Venkatesh PN, Chan WOY, Kumar D, Agrawal R, Chen Y, Fong SW, Singh A, Sun LJ, Tan SY, Chai LYA, Somani J, Lee B, Renia L, Ng LFP, Ramanathan K, Wang LF, Young B, Lye D, Singhal A, Prabhakar S. Longitudinal single cell atlas identifies complex temporal relationship between type I interferon response and COVID-19 severity. Nat Commun. 2024 01 18; 15(1):567.